Virtus Advisers LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD
Virtus Advisers LLC has made a new investment in ACADIA Pharmaceuticals Inc., purchasing over 44,000 shares valued at approximately $1.12 million. Other institutional investors like BlackRock and Norges Bank also significantly increased their stakes. Despite insider selling, analysts maintain a "Moderate Buy" consensus for ACADIA Pharmaceuticals, which recently beat earnings estimates.
Great Lakes Advisors LLC Purchases New Holdings in ACADIA Pharmaceuticals Inc. $ACAD
Great Lakes Advisors LLC has acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), purchasing 151,341 shares valued at approximately $3.83 million in the second quarter. Other institutional investors also adjusted their holdings in the biopharmaceutical company. Meanwhile, company insiders, including EVP Mark C. Schneyer and EVP Elizabeth H.Z. Thompson, have sold significant shares in recent transactions.
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year High - Here's What Happened
ACADIA Pharmaceuticals (NASDAQ:ACAD) recently hit a new 52-week high of $29.87, closing near $29.62, driven by positive analyst sentiment and strong financial results. The company's recent earnings exceeded expectations, reporting $0.18 EPS against an anticipated $0.07, and revenue grew 16.4% year-over-year to $308 million. Analysts maintain a "Moderate Buy" rating with an average price target of $34.19, despite some insider stock sales.
Rice Hall James & Associates LLC Purchases Shares of 618,887 ACADIA Pharmaceuticals Inc. $ACAD
Rice Hall James & Associates LLC acquired 618,887 shares of ACADIA Pharmaceuticals Inc. in the second quarter, valuing their new stake at approximately $15.7 million. This purchase gives the firm a 0.36% ownership in the biopharmaceutical company. ACADIA Pharmaceuticals reported strong quarterly earnings, beating consensus estimates, and analysts maintain a "Moderate Buy" rating despite recent insider share sales.
UBS raises Acadia Pharmaceuticals stock price target on trial optimism
UBS has increased its price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $49 from $45, maintaining a Buy rating due to increased optimism regarding its remlifanserin trial for Alzheimer’s disease psychosis. The firm raised the probability of success for the Phase 2 asset to 50% from 40% and adjusted risk-adjusted peak sales estimates to $1.6 billion. Acadia also reported strong Q2 2026 revenues and is expected to release remlifanserin trial data between September and October.
Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD)
ACADIA Pharmaceuticals (ACAD) reported mixed Q2 2026 results, with higher year-to-date revenue but lower net income compared to 2025. Despite this, the company raised its full-year 2026 revenue guidance, driven by strong performance from NUPLAZID and DAYBUE. While the increased guidance tightens the focus on near-term execution, the company's reliance on these two key drugs still poses a significant risk to its long-term investment narrative.
UBS raises Acadia Pharmaceuticals stock price target on trial optimism
UBS has increased its price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $49 from $45, maintaining a Buy rating, due to increased optimism for its drug remlifanserin in Alzheimer’s disease psychosis. The firm raised its probability of success for remlifanserin to 50% and its risk-adjusted peak sales estimates to $1.6 billion. Acadia also reported strong Q2 2026 revenues and positive analyst revisions from RBC Capital, Oppenheimer, and Citizens.
GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD
GSA Capital Partners LLP has initiated a new investment in ACADIA Pharmaceuticals Inc., purchasing 70,484 shares valued at approximately $1.78 million during the second quarter. This move is part of a broader trend, with several other hedge funds also adjusting their positions in the biopharmaceutical company. ACADIA Pharmaceuticals recently reported strong quarterly earnings, beating analyst expectations, and has received "Moderate Buy" ratings from analysts with an average target price of $33.69.
Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD
Empowered Funds LLC has made a new investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), acquiring 48,982 shares valued at approximately $1.09 million. This comes as institutional investors hold 96.71% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average price target of $33.69. Despite strong quarterly earnings, company insiders have sold a significant number of shares recently.
48,794 Shares in ACADIA Pharmaceuticals Inc. $ACAD Purchased by State of Wyoming
The State of Wyoming recently purchased 48,794 shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) valued at approximately $1.23 million during the second quarter. This move is part of broader institutional investment, as such entities now own 96.71% of the company's stock. Analysts maintain a "Moderate Buy" consensus for ACADIA, with an average price target of $33.69, following strong quarterly earnings that surpassed expectations.
Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Assenagon Asset Management S.A. significantly reduced its stake in ACADIA Pharmaceuticals Inc. by selling 57,075 shares, decreasing its holdings by 73.1%. Despite this, other institutional investors have either increased their positions or acquired new ones in ACADIA Pharmaceuticals. Insider selling also occurred, with executives Mark C. Schneyer and Elizabeth H.Z. Thompson selling shares, while analysts have generally maintained "buy" or "outperform" ratings with increased price targets for the company.
Bank of America Corp DE Acquires 332,325 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Bank of America Corp DE increased its stake in ACADIA Pharmaceuticals Inc. by 27.2%, purchasing an additional 332,325 shares to own a total of 1.55 million shares valued at $34.6 million. ACADIA Pharmaceuticals reported strong quarterly results with revenue up 16.4% year-over-year and adjusted earnings beating analyst estimates, contributing to a "Moderate Buy" consensus among analysts. Despite positive institutional investor sentiment and strong financial performance, company insiders sold a significant number of shares recently.
ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside
The average 12-month price target for ACADIA Pharmaceuticals Inc. (ACAD) stock has been lowered from $33.65 to $33.05 by 19 analysts, with a range of $17 to $41 per share. This new target suggests a potential 17% upside based on the August 14 closing price. The consensus rating among 20 analysts remains "Buy," comprising 15 Buys, 4 Holds, and 1 Sell.
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts
Argus has raised its target price for ACADIA Pharmaceuticals Inc. (ACAD) to $31.00, up from its previous rating. The biopharmaceutical company focuses on developing and commercializing medicines for central nervous system (CNS) disorders and rare diseases. This report, published on August 12, 2026, highlights their positive outlook on the stock, which is currently priced at $28.38.
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data
ACADIA Pharmaceuticals is expanding the commercial reach of its therapies, DAYBUE and NUPLAZID, and preparing for upcoming clinical data for remlifanserin in Alzheimer’s disease psychosis. The company has increased its sales force for NUPLAZID, a treatment for Parkinson's disease psychosis, and is focusing on patient persistence and new formulations for DAYBUE, a Rett syndrome treatment. ACADIA is also pursuing European and Japanese market expansion for DAYBUE and anticipates Phase II data for remlifanserin in Alzheimer's disease psychosis soon, while evaluating business development opportunities.
Royal Bank of Canada Trims Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD
Royal Bank of Canada reduced its stake in ACADIA Pharmaceuticals Inc. by 23.3% in the first quarter, selling 67,699 shares but still holding 223,155 shares valued at $4.97 million. This comes as institutional investors own 96.71% of the company. ACADIA Pharmaceuticals reported strong quarterly earnings, beating estimates with $0.18 per share and revenue up 16.4% year-over-year to $308 million, leading to favorable analyst ratings and a "Moderate Buy" consensus.
ACADIA Pharmaceuticals (ACAD) On Raised 2026 Guidance And Strong Results Looks Undervalued
ACADIA Pharmaceuticals (ACAD) has seen its stock gain attention after raising its 2026 revenue guidance to between US$1.24 billion and US$1.30 billion, driven by strong second-quarter results. The company's pipeline, with nine disclosed programs, suggests diversification beyond its current key products, contributing to a fair value estimate of $33.25, indicating it is currently undervalued at $29.41. However, investors should be aware of risks such as its reliance on NUPLAZID revenue and upcoming trial results for remlifanserin.
Acadia Pharmaceuticals stock hits 52-week high at $29.81 By Investing.com
Acadia Pharmaceuticals (ACAD) stock reached a new 52-week high of $29.81, trading at $29.77, marking a 36% surge over the last six months. This growth is supported by strong Q2 2026 revenues of $308 million, exceeding estimates, driven by robust sales of Daybue. Analysts have revised earnings upwards and several firms, including RBC Capital and Oppenheimer, have increased their price targets for the company.
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $41.00 Price Target at Needham & Company LLC
Needham & Company LLC has raised its price target for ACADIA Pharmaceuticals (NASDAQ:ACAD) from $38.00 to $41.00, maintaining a "Buy" rating, which suggests a potential upside of 39.41%. This comes as the biopharmaceutical company exceeded quarterly earnings expectations, reporting $0.18 EPS against an anticipated $0.07, and revenue of $308 million, marking a 16.4% year-over-year increase. Despite favorable analyst sentiment with a "Moderate Buy" consensus, insiders have sold shares worth approximately $1.13 million in the last 90 days.
ACADIA Pharmaceuticals (ACAD) On Raised 2026 Guidance And Strong Results Looks Undervalued
ACADIA Pharmaceuticals (ACAD) has seen its stock gain investor attention after raising its 2026 earnings guidance and reporting strong second-quarter results. The company now projects 2026 revenue between US$1.24b and US$1.30b, with a significant portion coming from NUPLAZID and DAYBUE. Despite its strong performance and pipeline, Simply Wall St suggests ACAD is still undervalued by 11.5% compared to a fair value of $33.25.
Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating
Morgan Stanley has increased its price target for ACADIA Pharmaceuticals (ACAD) from $26 to $27, while maintaining an Equalweight rating on the stock. This adjustment reflects a modest positive outlook on the company's valuation by the firm.
Janus Henderson Group PLC Decreases Stake in ACADIA Pharmaceuticals Inc. $ACAD
Janus Henderson Group PLC significantly reduced its stake in ACADIA Pharmaceuticals Inc. by 82.3% in the first quarter, selling over 238,000 shares. Despite this, other major institutional investors increased their positions, and collective institutional ownership remains high at 96.71%. ACADIA Pharmaceuticals reported strong quarterly earnings, beating estimates with $0.18 per share and a 16.4% increase in revenue.
ACADIA Pharmaceuticals Inc. Revenue Breakdown – BIVA:ACAD
ACADIA Pharmaceuticals Inc. (BIVA:ACAD) generated 19.32 billion MXN in revenue last year, primarily from its Innovative Medicines segment. The company's revenue decreased slightly from 19.97 billion MXN the previous year. The United States was the largest contributor to revenue, accounting for the entire 19.32 billion MXN.
Sei Investments Co. Lowers Stock Position in ACADIA Pharmaceuticals Inc. $ACAD
Sei Investments Co. significantly reduced its stake in ACADIA Pharmaceuticals Inc. by 31.0% in the first quarter, selling 47,740 shares but still retaining 106,390 shares valued at approximately $2.37 million. Despite this reduction by one institutional investor, others have either increased or initiated positions, and institutional investors collectively own 96.71% of the company. Analysts maintain a "Moderate Buy" rating with an average price target of $33.44, following strong quarterly results where ACADIA beat EPS and revenue expectations.
Acadia Pharmaceuticals (ACAD) Stock Gets Fair Value Bump As Analysts Back Daybue Growth
Acadia Pharmaceuticals (ACAD) has seen its fair value price target increased from US$31.80 to US$33.25 per share, driven by positive analyst commentary and strong performance of its drug Daybue. Analysts highlighted Daybue's revenue, the positive European opinion for trofinetide, and anticipated remlifanserin data as key factors, though some expressed caution regarding remlifanserin's efficacy and the inherent risks. The updated valuation reflects adjustments in revenue growth assumptions and net profit margin.
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) recently reported quarterly results that exceeded expectations, with revenues beating forecasts by 4.2% and statutory profit significantly surpassing analyst predictions. Following these strong results, analysts have updated their earnings models, showing increased optimism for the company's future, particularly with a massive increase in earnings per share forecasts for 2026. Despite the upgraded earnings estimates, the consensus price target for ACADIA Pharmaceuticals remained unchanged at US$33.50, suggesting that the improved performance has not yet impacted long-term valuation expectations.
State Street Corporation (ACAD) discloses 5.3% Acadia Pharma stake on 13G
State Street Corporation has disclosed a 5.3% beneficial ownership stake in Acadia Pharmaceuticals Inc. (ACAD) through a Schedule 13G SEC filing. This translates to 9,076,212 shares of common stock, managed across various State Street Global Advisors entities. The filing indicates shared voting power over 8,679,785 shares and shared dispositive power over all beneficially owned shares, with no sole voting or dispositive power.
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reported strong quarterly results, with revenues exceeding expectations and statutory profit significantly above analyst forecasts. Following these positive results, analysts have increased their earnings per share forecasts for 2026, indicating increased optimism for the company's future. Despite the upgraded earnings estimates, the consensus price target remained unchanged, suggesting that analysts do not foresee a long-term impact on the company's valuation.
Acadia CFO Mark Schneyer sells $587k in company stock
Mark C. Schneyer, CFO of ACADIA PHARMACEUTICALS INC, sold over $587,000 worth of company stock through a pre-arranged trading plan in early August 2026, while also exercising stock options. These transactions occurred as Acadia's stock traded near its 52-week high, coinciding with strong Q2 2026 revenue and several analyst price target increases.
H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating
H.C. Wainwright has reiterated a Buy rating and a $37.00 price target for Acadia Pharmaceuticals (NASDAQ: ACAD). The stock is currently trading near its 52-week high, with strong momentum. The firm highlighted the recent closure of enrollment for the Phase 2 RADIANT trial, with data expected around September or October, and noted that Acadia's recent Q2 2026 revenue surpassed estimates, leading analysts to raise price targets.
RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $36, Maintains Outperform Rating
RBC Capital has adjusted its price target for ACADIA Pharmaceuticals (ACAD) shares to $37, up from the previous $36. The firm simultaneously maintained its Outperform rating on the company's stock. This revision reflects RBC Capital's updated valuation of ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals (ACAD) Stock Jumps As Valuation Gap Draws Focus
ACADIA Pharmaceuticals (ACAD) saw its stock jump 6.1% after strong Q2 2026 earnings, reporting increased revenue and net income. The article highlights a significant valuation gap with a P/E of 13 against a discounted cash flow estimate of US$87.67 per share, suggesting potential for long-term growth. The company's key drugs, DAYBUE and NUPLAZID, and the progress of its pipeline drug remlifanserin, are driving momentum despite concerns about product concentration and clinical risks.
ACADIA PHARMACEUTICALS INC Quarterly Earnings Report
ACADIA PHARMACEUTICALS INC (ACAD) has released its unaudited quarterly earnings report for the three and six months ended June 30, 2026. The company reported sufficient liquidity to fund planned operations beyond the next 12 months with $956.5 million in cash, cash equivalents, and investment securities as of June 30, 2026. Net product sales for the six months ended June 30, 2026, totaled $576.0 million, primarily from NUPLAZID and DAYBUE products, indicating continued growth in these key revenue streams.
ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $33.25, Implies 22% Upside
ACADIA Pharmaceuticals Inc.'s average stock price target has been raised from $32.95 to $33.25 by 20 analysts, with a range of $17 to $45 per share. This new target implies a potential upside of approximately 22% based on the August 4 closing price. The consensus rating for ACADIA Pharmaceuticals Inc. remains a "Buy" among 21 analysts.
ACADIA PHARMACEUTICALS INC SEC Filing (Aug 5, 2026)
This article reports on an SEC Form 144 filing by ACADIA PHARMACEUTICALS INC (ACAD) on August 5, 2026, indicating a proposed sale of 5849 shares of common stock acquired through a stock option exercise, with an aggregate market value of $158,800.35, to be sold via Piper Sandler & Co Inc on Nasdaq. The filing has a neutral sentiment and impact according to AI-generated analysis.
ACADIA Pharmaceuticals Inc. Revenue Breakdown – BMV:ACAD
ACADIA Pharmaceuticals Inc. (BMV:ACAD) generated 19.32 billion MXN in revenue last year, primarily from its Innovative Medicines segment. The United States was the largest contributor to this revenue, accounting for the entire 19.32 billion MXN. This revenue figure is a slight decrease from the 19.97 billion MXN reported in the previous year.
RBC Capital raises Acadia Pharmaceuticals price target on strong Daybue sales
RBC Capital has increased its price target for Acadia Pharmaceuticals (NASDAQ: ACAD) to $37 from $36, maintaining an Outperform rating, due to better-than-expected Daybue sales. The company's strong performance, including $125 million in Daybue sales and solid Nuplazid performance, led to an increase in its 2026 guidance. Other firms like Oppenheimer and Citizens have also raised their price targets, reflecting a positive outlook for Acadia Pharmaceuticals.
Acadia Pharmaceuticals stock hits 52-week high at 28.4 USD
Acadia Pharmaceuticals Inc. (ACAD) stock reached a new 52-week high of $28.35, currently trading at $28.92, reflecting a 19.75% increase over the past year. InvestingPro analysis suggests the stock is undervalued, boasting an attractive P/E ratio of 12.23 and a low PEG ratio of 0.2. This performance follows strong Q2 2026 revenue of $308 million, driven by Daybue sales, leading analysts like Oppenheimer and Citizens to raise price targets and the company to revise its 2026 guidance upwards.
ACADIA Pharmaceuticals Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ACAD) 2026-08-05
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its Q2 2026 earnings call presentation, detailing its financial results. The company reported an EPS of $0.18, beating estimates by $0.14, and revenue of $307.96 million, a 16.40% year-over-year increase, surpassing expectations by $12.44 million. This presentation provides investors with key insights into the company's performance for the quarter.
RBC Capital Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $36, Maintains Outperform Rating
RBC Capital has increased its price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) to $37 from $36, while reiterating an Outperform rating. This adjustment follows ACADIA Pharmaceuticals' Q2 Daybue sales exceeding expectations due to Stix Formulation uptake, which supports an improved outlook for the company.
ACADIA PHARMACEUTICALS, INC. : OPPENHEIMER RAISES TARGET PRICE TO $25 FROM $23
Oppenheimer has increased its target price for ACADIA Pharmaceuticals, Inc. from $23 to $25. This update was reported by Reuters on August 5, 2026. The article includes a disclaimer stating that the content reflects only the author's opinion and is not investment advice.
Earnings call transcript: ACADIA tops Q2 2026 revenue forecast as shares rise
ACADIA Pharmaceuticals reported strong Q2 2026 results, with revenue reaching $308 million, surpassing analyst forecasts. The growth was primarily driven by robust sales of DAYBUE for Rett syndrome and NUPLAZID for Parkinson’s disease psychosis, leading the company to raise its 2026 DAYBUE sales guidance and trim R&D spending plans. The company also highlighted progress in its pipeline, particularly with remlifanserin for Alzheimer's disease psychosis, and confirmed plans for DAYBUE's European launch.
ACADIA Pharmaceuticals Q2 2026 Earnings Call Transcript
ACADIA Pharmaceuticals reported strong Q2 2026 financial results with total revenues of $308 million, a 17% year-over-year increase, driven by robust sales of DAYBUE and NUPLAZID. DAYBUE sales grew 30% to $125 million, supported by the new STIX formulation and a positive CHMP opinion in Europe, leading to increased 2026 guidance. NUPLAZID sales rose 10% to $183 million, with new
ACADIA Pharmaceuticals Q2 Earnings Call Highlights
ACADIA Pharmaceuticals reported strong Q2 2026 revenue of $308 million, a 17% year-over-year increase, driven by sales of DAYBUE and NUPLAZID. The company raised its full-year DAYBUE sales outlook, anticipating European commercial sales in Q4, and provided updates on its remlifanserin pipeline, with phase II data expected soon. ACADIA also detailed its financial position, including $956 million in cash and revised R&D expense guidance.
Earnings Flash (ACAD) Acadia Pharmaceuticals Inc. Reports Q2 Revenue $308.0M, vs. FactSet Est of $295.5M
Acadia Pharmaceuticals Inc. (ACAD) reported its Q2 revenue at $308.0 million, surpassing the FactSet estimate of $295.5 million. The company's stock symbol is ACAD, and it operates in the Biotechnology & Medical Research sector. This positive financial performance was also accompanied by an increase in earnings guidance for the fiscal year 2026.
ACADIA Pharmaceuticals (ACAD) Stock Looks Cheap On Earnings Yet Weak On Recent Returns
ACADIA Pharmaceuticals (ACAD) stock has seen a 38.5% gain over five years but has delivered softer returns recently. Despite this, Simply Wall St's analysis suggests the stock appears relatively cheap, trading at 11.7x earnings, well below the biotech sector average, and passing multiple valuation tests. The company's future revenue potential is tied to its dementia-related psychosis drug candidate ACP-204, though competition poses a risk, and the market maintains a cautious stance on its valuation.
ETFs Investing in ACADIA Pharmaceuticals Inc. Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold stocks of ACADIA Pharmaceuticals Inc. (ACAD). The list is sorted by market value and includes various details for each ETF, such as issuer, management style, focus, expense ratio, assets under management, and price performance. It aims to help investors identify funds that offer exposure to ACADIA Pharmaceuticals with potentially lower risk.
ACADIA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Ndu Adora
This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for Director Ndu Adora at ACADIA Pharmaceuticals. It indicates a change in ownership of securities for the named individual. The document itself is not provided, only its existence is noted.
Acadia Pharmaceuticals EVP Thompson sells $432,662 in stock
Elizabeth H.Z. Thompson, EVP at ACADIA PHARMACEUTICALS INC, sold company common stock worth approximately $432,662 to cover withholding taxes related to vesting restricted stock units. This transaction followed her acquisition of 32,272 shares through RSU vesting. The company also recently received Fast Track designation for remlifanserin and completed enrollment for its RADIANT Phase 2 trial.
Acadia Pharmaceuticals EVP Thompson sells $432,662 in stock By Investing.com
Elizabeth H.Z. Thompson, EVP and Head of R&D at Acadia Pharmaceuticals, sold $432,662 worth of company stock to cover taxes related to restricted stock unit vesting. This follows her acquisition of 32,272 shares through vesting. The company has also recently received Fast Track designation for remlifanserin and a positive opinion for DAYBU in Europe, while analysts have adjusted price targets.
